Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LABD vs LABU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LABU Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

LABU Overall Winner 6-Pillar Tally: LABD 0 – 0 LABU (6 Tie) Matrix Metrics: LABD 1 – 2 LABU

As of Nov 16, 2026, Direxion Daily S&P Biotech Bull 3X Shares (LABU) is the stronger overall head-to-head candidate over Direxion Daily S&P Biotech Bear 3X Shares (LABD) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). LABD carries a Unified Composite Score of 51.2/100 (HOLD) at $8.09 (N/M Forward P/E, N/A operating margin), whereas LABU carries 49.4/100 (HOLD) at $195.22 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While LABD currently prints a higher short-term Unified Composite Score (51.2/100 HOLD vs. LABU 49.4/100 HOLD), LABU captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: LABD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.7); meanwhile LABU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LABD vs LABU
LABD NYSE Arca
Direxion Daily S&P Biotech Bear 3X Shares
Institutional Equity
$8.09
+9.03% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -3.71β · 120% Vol
Unified Composite Score
51.2 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.0% over 20 days), RSI 56
RSI-14: 55.7 · SMA20: $7.24 · SMA50: $7.44
LABU NYSE Arca Head-to-Head Winner
Direxion Daily S&P Biotech Bull 3X Shares
Institutional Equity
$195.22
-9.13% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.71β · 119% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $232.97 · SMA50: $242.77

6-Pillar Scorecard Institutional Category Breakdown (LABD 0 – 0 LABU)

Columns: Metric · LABD · LABU
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 76.1% (18th %ile) 86.4% (12th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LABD (1) vs LABU (2)
Institutional Metric LABD LABU Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
10% ($6–$29) 33% ($124–$342) Stronger Trend LABU
Beta / 30D Volatility
Risk Regime
-3.71β · 120% Vol 3.71β · 119% Vol Lower Realized Risk LABU
Unified Institutional Score
Composite Signal
51.2 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite LABD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LABU +7.88 pp
LABD: -9.71% · LABU: -1.83%
3M Horizon LABD +45.04 pp
LABD: +12.36% · LABU: -32.68%
6M Horizon LABU +70.27 pp
LABD: -48.73% · LABU: +21.54%
1Y Horizon LABU +125.3 pp
LABD: -71.33% · LABU: +53.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LABD vs LABU. Trailing 12-month operating profitability (LABD N/A vs LABU N/A) and valuation multiples (LABD N/M vs LABU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LABD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
LABU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LABD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.1%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LABD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LABU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 86.4%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LABU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LABD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LABU Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LABD vs LABU Key Questions & Quantitative Answers

As of Nov 16, 2026, Direxion Daily S&P Biotech Bull 3X Shares (LABU) is the stronger overall head-to-head candidate over Direxion Daily S&P Biotech Bear 3X Shares (LABD) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). LABD carries a Unified Composite Score of 51.2/100 (HOLD) at $8.09 (N/M Forward P/E, N/A operating margin), whereas LABU carries 49.4/100 (HOLD) at $195.22 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While LABD currently prints a higher short-term Unified Composite Score (51.2/100 HOLD vs. LABU 49.4/100 HOLD), LABU captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: LABD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.7); meanwhile LABU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LABD and LABU split Growth & Scale metrics: LABD posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LABU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, LABD generates N/A in USD-normalized revenue versus N/A for LABU. In operating R&D and SG&A reinvestment, LABD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LABU.

LABD and LABU trade at balanced relative valuation multiples. LABD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LABU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LABD (N/A ROE) versus LABU (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, LABD carries 76.1% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-3.71β · 120% Vol realized risk). By comparison, LABU carries 86.4% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.71β · 119% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.